Frontlight ResearchEarly access
Taking peoplePhase 2/3
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Key facts
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Where
- Japan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 315 people, planned
- Started
- 3 Sept 2025
- Expected to end
- Aug 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- EB-1020 (Centanafadine) low dose
- EB-1020 (Centanafadine) high dose
- Placebo
- Record updated
- 23 December 2025
Who can take part
- Age
- 6 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participants with a primary diagnosis of ADHD based on DSM-5 diagnostic criteria, differentiated from other mental disorders using the MINI-KID, excluding other specified ADHD or unspecified ADHD
- Participants with a symptom total raw score of>=28 (if not receiving any pharmacological treatment for ADHD) or>=22 (if receiving pharmacological treatment for ADHD) on the ADHD Rating Scale Version 5 (ADHD-RS-5) at screening
- Participants with a symptom total raw score of>=28 on the ADHD-RS-5 at baseline
- Participants with a score of 4 or higher on the Clinical Global Impression Severity - ADHD (CGI-S-ADHD) at baseline
Who cannot take part
- Participants with a diagnosis of major depressive disorder (MDD), based on the DSM-5 diagnostic criteria who currently have a major depressive episode, or who have required treatment for MDD within the past 3 months prior to screening; Also, participants who, in the judgment of the investigator or subinvestigator, may have a worsening of MDD during the trial or may require treatment during the trial period
- Participants who cannot agree to discontinuation of prohibited concomitant medication, such as ADHD medication or antidepressants
- Participants determined to have the following diseases based on an interview using the MINI-KID; Tourette's disorder; Panic disorder; Conduct disorder; Psychotic disorder; Post-traumatic stress disorder; Bipolar disorder
- Participants with a generalized anxiety disorder requiring pharmacotherapy, based on the DSM-5 diagnostic criteria
- Participants with an autism spectrum disorder based on the DSM-5 diagnostic criteria
- Participants with a personality disorder, oppositional defiant disorder, or obsessive-compulsive disorder that is the primary focus of treatment, based on the DSM-5 diagnostic criteria
- Participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence; Active suicidal ideation as evidenced by an answer of "yes" on Questions 4 or 5 (over the last 6 months) on the section of suicidal ideation or a history of suicidal behavior (over the last 6 months) on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening
- Participants with a diagnosis of substance use disorder; Platelets <= 130,000/mm3; Hemoglobin <= 11.2 g/dL; Neutrophils, absolute <= 1000/mm3; AST > 2 x ULN; ALT > 2 x ULN; eGFR < 45 mL/min/1.73 m2, calculated by the CKiD U25 equation; CPK >= 2 x ULN (except for the cases that the medical monitor determined that participant's inclusion is possible based on the discussion about the participant's condition with the investigator or subinvestigator); Abnormal values for both free T4 and TSH
- Participants who have a positive pregnancy test result at baseline
- Participants who have a diagnosis of intellectual disability with an intelligence quotient (IQ) score less than 70
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
The 3 groups in the trial
- EB-1020(QD XR capsules) low doseTreatment being tested
Treatment: EB-1020 (Centanafadine) low dose
- EB-1020(QD XR capsules) high doseTreatment being tested
Treatment: EB-1020 (Centanafadine) high dose
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Japan-China Joint Trial to Evaluate the Efficacy and Safety of Two Dose Levels of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention-deficit/Hyperactivity Disorder
- Fit questions
- Built from NCT07086313, who can take part
- Record updated
- 23 December 2025